ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 84 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 2.93 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $169,944 | -31.8% | 21,900 | -49.9% | 0.00% | -100.0% |
| Q1 2023 | $249,090 | -71.2% | 43,700 | -70.3% | 0.00% | -66.7% |
| Q4 2022 | $865,241 | +70.3% | 146,900 | -7.4% | 0.00% | +50.0% |
| Q3 2022 | $508,000 | -40.4% | 158,600 | -16.6% | 0.00% | 0.0% |
| Q2 2022 | $852,000 | +45.4% | 190,200 | +73.2% | 0.00% | +100.0% |
| Q1 2022 | $586,000 | +4.3% | 109,800 | +187.4% | 0.00% | 0.0% |
| Q4 2021 | $562,000 | -29.7% | 38,200 | 0.0% | 0.00% | -50.0% |
| Q3 2021 | $799,000 | +24.8% | 38,200 | +5.5% | 0.00% | +100.0% |
| Q2 2021 | $640,000 | +110.5% | 36,205 | +192.0% | 0.00% | 0.0% |
| Q1 2021 | $304,000 | -27.6% | 12,400 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $420,000 | +20.7% | 12,400 | -10.8% | 0.00% | 0.0% |
| Q3 2020 | $348,000 | -25.8% | 13,900 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $469,000 | – | 13,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $161,403,000 | 14.64% |
| Invus Financial Advisors, LLC | 1,007,575 | $34,106,000 | 14.26% |
| Euclidean Capital LLC | 1,400,435 | $47,405,000 | 10.04% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $20,387,000 | 8.63% |
| EcoR1 Capital, LLC | 3,092,218 | $104,672,000 | 5.63% |
| Ally Bridge Group (NY) LLC | 413,061 | $13,982,000 | 2.40% |
| Asymmetry Capital Management, L.P. | 67,210 | $2,275,000 | 1.04% |
| Orbimed Advisors | 2,921,967 | $98,909,000 | 0.86% |
| Casdin Capital, LLC | 601,515 | $20,361,000 | 0.60% |
| EMERALD ADVISERS, LLC | 522,302 | $17,680,000 | 0.59% |